Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ETN201
- Development stage
- Preclinical
- Lead developer
- Etnova Therapeutics
- Modality
- Small Molecules
01
Overview
ETN201 is a preclinical-stage small molecule drug candidate being developed by Etnova Therapeutics for the treatment of thrombosis. As a first-in-class therapeutic candidate, it is intended for the treatment of blood clots (thrombi). The program is currently in the early stages of research and development, and while the specific molecular target has not been publicly disclosed, the asset is part of Etnova's pipeline focusing on innovative treatments for vascular and neurological disorders. The company, a spin-off from the Korea Institute of Science and Technology (KIST), aims to address unmet needs in thrombus management through novel mechanisms.
Beyond the preview
Go deeper on ETN201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ETN201.